-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Compass Therapeutics, Maintains $12 Price Target

Benzinga·03/24/2026 13:22:22
Listen to the news
Guggenheim analyst Michael Schmidt reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $12 price target.